List of Tables
Table 1. Global Neurodegenerative Diseases Drug Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Immunomodulator
Table 3. Key Players of Interferons
Table 4. Key Players of Decarboxylase Inhibitors
Table 5. Key Players of Dopamine Agonists
Table 6. Key Players of Others
Table 7. Global Neurodegenerative Diseases Drug Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 8. Global Neurodegenerative Diseases Drug Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 9. Global Neurodegenerative Diseases Drug Market Size by Region (2017-2022) & (US$ Million)
Table 10. Global Neurodegenerative Diseases Drug Market Share by Region (2017-2022)
Table 11. Global Neurodegenerative Diseases Drug Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 12. Global Neurodegenerative Diseases Drug Market Share by Region (2023-2028)
Table 13. Neurodegenerative Diseases Drug Market Trends
Table 14. Neurodegenerative Diseases Drug Market Drivers
Table 15. Neurodegenerative Diseases Drug Market Challenges
Table 16. Neurodegenerative Diseases Drug Market Restraints
Table 17. Global Neurodegenerative Diseases Drug Revenue by Players (2017-2022) & (US$ Million)
Table 18. Global Neurodegenerative Diseases Drug Revenue Share by Players (2017-2022)
Table 19. Global Top Neurodegenerative Diseases Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Drug as of 2021)
Table 20. Ranking of Global Top Neurodegenerative Diseases Drug Companies by Revenue (US$ Million) in 2021
Table 21. Global 5 Largest Players Market Share by Neurodegenerative Diseases Drug Revenue (CR5 and HHI) & (2017-2022)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Neurodegenerative Diseases Drug Product Solution and Service
Table 24. Date of Enter into Neurodegenerative Diseases Drug Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Neurodegenerative Diseases Drug Market Size by Type (2017-2022) & (US$ Million)
Table 27. Global Neurodegenerative Diseases Drug Revenue Market Share by Type (2017-2022)
Table 28. Global Neurodegenerative Diseases Drug Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 29. Global Neurodegenerative Diseases Drug Revenue Market Share by Type (2023-2028)
Table 30. Global Neurodegenerative Diseases Drug Market Size by Application (2017-2022) & (US$ Million)
Table 31. Global Neurodegenerative Diseases Drug Revenue Share by Application (2017-2022)
Table 32. Global Neurodegenerative Diseases Drug Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 33. Global Neurodegenerative Diseases Drug Revenue Share by Application (2023-2028)
Table 34. North America Neurodegenerative Diseases Drug Market Size by Type (2017-2022) & (US$ Million)
Table 35. North America Neurodegenerative Diseases Drug Market Size by Type (2023-2028) & (US$ Million)
Table 36. North America Neurodegenerative Diseases Drug Market Size by Application (2017-2022) & (US$ Million)
Table 37. North America Neurodegenerative Diseases Drug Market Size by Application (2023-2028) & (US$ Million)
Table 38. North America Neurodegenerative Diseases Drug Market Size by Country (2017-2022) & (US$ Million)
Table 39. North America Neurodegenerative Diseases Drug Market Size by Country (2023-2028) & (US$ Million)
Table 40. Europe Neurodegenerative Diseases Drug Market Size by Type (2017-2022) & (US$ Million)
Table 41. Europe Neurodegenerative Diseases Drug Market Size by Type (2023-2028) & (US$ Million)
Table 42. Europe Neurodegenerative Diseases Drug Market Size by Application (2017-2022) & (US$ Million)
Table 43. Europe Neurodegenerative Diseases Drug Market Size by Application (2023-2028) & (US$ Million)
Table 44. Europe Neurodegenerative Diseases Drug Market Size by Country (2017-2022) & (US$ Million)
Table 45. Europe Neurodegenerative Diseases Drug Market Size by Country (2023-2028) & (US$ Million)
Table 46. Asia Pacific Neurodegenerative Diseases Drug Market Size by Type (2017-2022) & (US$ Million)
Table 47. Asia Pacific Neurodegenerative Diseases Drug Market Size by Type (2023-2028) & (US$ Million)
Table 48. Asia Pacific Neurodegenerative Diseases Drug Market Size by Application (2017-2022) & (US$ Million)
Table 49. Asia Pacific Neurodegenerative Diseases Drug Market Size by Application (2023-2028) & (US$ Million)
Table 50. Asia Pacific Neurodegenerative Diseases Drug Market Size by Region (2017-2022) & (US$ Million)
Table 51. Asia Pacific Neurodegenerative Diseases Drug Market Size by Region (2023-2028) & (US$ Million)
Table 52. Latin America Neurodegenerative Diseases Drug Market Size by Type (2017-2022) & (US$ Million)
Table 53. Latin America Neurodegenerative Diseases Drug Market Size by Type (2023-2028) & (US$ Million)
Table 54. Latin America Neurodegenerative Diseases Drug Market Size by Application (2017-2022) & (US$ Million)
Table 55. Latin America Neurodegenerative Diseases Drug Market Size by Application (2023-2028) & (US$ Million)
Table 56. Latin America Neurodegenerative Diseases Drug Market Size by Country (2017-2022) & (US$ Million)
Table 57. Latin America Neurodegenerative Diseases Drug Market Size by Country (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Neurodegenerative Diseases Drug Market Size by Type (2017-2022) & (US$ Million)
Table 59. Middle East and Africa Neurodegenerative Diseases Drug Market Size by Type (2023-2028) & (US$ Million)
Table 60. Middle East and Africa Neurodegenerative Diseases Drug Market Size by Application (2017-2022) & (US$ Million)
Table 61. Middle East and Africa Neurodegenerative Diseases Drug Market Size by Application (2023-2028) & (US$ Million)
Table 62. Middle East and Africa Neurodegenerative Diseases Drug Market Size by Country (2017-2022) & (US$ Million)
Table 63. Middle East and Africa Neurodegenerative Diseases Drug Market Size by Country (2023-2028) & (US$ Million)
Table 64. Biogen Company Details
Table 65. Biogen Business Overview
Table 66. Biogen Neurodegenerative Diseases Drug Product
Table 67. Biogen Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
Table 68. Biogen Recent Developments
Table 69. Pfizer Company Details
Table 70. Pfizer Business Overview
Table 71. Pfizer Neurodegenerative Diseases Drug Product
Table 72. Pfizer Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
Table 73. Pfizer Recent Developments
Table 74. Roche Company Details
Table 75. Roche Business Overview
Table 76. Roche Neurodegenerative Diseases Drug Product
Table 77. Roche Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
Table 78. Roche Recent Developments
Table 79. Novartis Company Details
Table 80. Novartis Business Overview
Table 81. Novartis Neurodegenerative Diseases Drug Product
Table 82. Novartis Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
Table 83. Novartis Recent Developments
Table 84. Sanofi Company Details
Table 85. Sanofi Business Overview
Table 86. Sanofi Neurodegenerative Diseases Drug Product
Table 87. Sanofi Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
Table 88. Sanofi Recent Developments
Table 89. Teva Pharmaceuticals Company Details
Table 90. Teva Pharmaceuticals Business Overview
Table 91. Teva Pharmaceuticals Neurodegenerative Diseases Drug Product
Table 92. Teva Pharmaceuticals Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
Table 93. Teva Pharmaceuticals Recent Developments
Table 94. Orion Pharma Ltd Company Details
Table 95. Orion Pharma Ltd Business Overview
Table 96. Orion Pharma Ltd Neurodegenerative Diseases Drug Product
Table 97. Orion Pharma Ltd Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
Table 98. Orion Pharma Ltd Recent Developments
Table 99. UCB S.A Company Details
Table 100. UCB S.A Business Overview
Table 101. UCB S.A Neurodegenerative Diseases Drug Product
Table 102. UCB S.A Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
Table 103. UCB S.A Recent Developments
Table 104. ACADIA Pharmaceuticals Inc. Company Details
Table 105. ACADIA Pharmaceuticals Inc. Business Overview
Table 106. ACADIA Pharmaceuticals Inc. Neurodegenerative Diseases Drug Product
Table 107. ACADIA Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
Table 108. ACADIA Pharmaceuticals Inc. Recent Developments
Table 109. Lundbeck Pharmaceuticals Italy S.p.A. Company Details
Table 110. Lundbeck Pharmaceuticals Italy S.p.A. Business Overview
Table 111. Lundbeck Pharmaceuticals Italy S.p.A. Neurodegenerative Diseases Drug Product
Table 112. Lundbeck Pharmaceuticals Italy S.p.A. Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
Table 113. Lundbeck Pharmaceuticals Italy S.p.A. Recent Developments
Table 114. Mitsubishi Tanabe Pharma America Company Details
Table 115. Mitsubishi Tanabe Pharma America Business Overview
Table 116. Mitsubishi Tanabe Pharma America Neurodegenerative Diseases Drug Product
Table 117. Mitsubishi Tanabe Pharma America Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
Table 118. Mitsubishi Tanabe Pharma America Recent Developments
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neurodegenerative Diseases Drug Market Share by Type: 2021 VS 2028
Figure 2. Immunomodulator Features
Figure 3. Interferons Features
Figure 4. Decarboxylase Inhibitors Features
Figure 5. Dopamine Agonists Features
Figure 6. Others Features
Figure 7. Global Neurodegenerative Diseases Drug Market Share by Application: 2021 VS 2028
Figure 8. Multiple Sclerosis Case Studies
Figure 9. Parkinson’s Disease Case Studies
Figure 10. Alzheimer’s Disease Case Studies
Figure 11. Spinal Muscular Atrophy (SMA) Case Studies
Figure 12. Others Case Studies
Figure 13. Neurodegenerative Diseases Drug Report Years Considered
Figure 14. Global Neurodegenerative Diseases Drug Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 15. Global Neurodegenerative Diseases Drug Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 16. Global Neurodegenerative Diseases Drug Market Share by Region: 2021 VS 2028
Figure 17. Global Neurodegenerative Diseases Drug Market Share by Players in 2021
Figure 18. Global Top Neurodegenerative Diseases Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Drug as of 2021)
Figure 19. The Top 10 and 5 Players Market Share by Neurodegenerative Diseases Drug Revenue in 2021
Figure 20. North America Neurodegenerative Diseases Drug Market Size YoY (2017-2028) & (US$ Million)
Figure 21. North America Neurodegenerative Diseases Drug Market Size Market Share by Type (2017-2028)
Figure 22. North America Neurodegenerative Diseases Drug Market Size Market Share by Application (2017-2028)
Figure 23. North America Neurodegenerative Diseases Drug Market Size Share by Country (2017-2028)
Figure 24. United States Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Canada Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. Europe Neurodegenerative Diseases Drug Market Size YoY (2017-2028) & (US$ Million)
Figure 27. Europe Neurodegenerative Diseases Drug Market Size Market Share by Type (2017-2028)
Figure 28. Europe Neurodegenerative Diseases Drug Market Size Market Share by Application (2017-2028)
Figure 29. Europe Neurodegenerative Diseases Drug Market Size Share by Country (2017-2028)
Figure 30. Germany Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. France Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. U.K. Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Italy Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Russia Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Nordic Countries Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Asia-Pacific Neurodegenerative Diseases Drug Market Size YoY (2017-2028) & (US$ Million)
Figure 37. Asia Pacific Neurodegenerative Diseases Drug Market Size Market Share by Type (2017-2028)
Figure 38. Asia Pacific Neurodegenerative Diseases Drug Market Size Market Share by Application (2017-2028)
Figure 39. Asia Pacific Neurodegenerative Diseases Drug Market Size Share by Region (2017-2028)
Figure 40. China Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Japan Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. South Korea Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Southeast Asia Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. India Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. Australia Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 46. Latin America Neurodegenerative Diseases Drug Market Size YoY (2017-2028) & (US$ Million)
Figure 47. Latin America Neurodegenerative Diseases Drug Market Size Market Share by Type (2017-2028)
Figure 48. Latin America Neurodegenerative Diseases Drug Market Size Market Share by Application (2017-2028)
Figure 49. Latin America Neurodegenerative Diseases Drug Market Size Share by Country (2017-2028)
Figure 50. Mexico Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 51. Brazil Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 52. Middle East & Africa Neurodegenerative Diseases Drug Market Size YoY (2017-2028) & (US$ Million)
Figure 53. Middle East and Africa Neurodegenerative Diseases Drug Market Size Market Share by Type (2017-2028)
Figure 54. Middle East and Africa Neurodegenerative Diseases Drug Market Size Market Share by Application (2017-2028)
Figure 55. Middle East and Africa Neurodegenerative Diseases Drug Market Size Share by Country (2017-2028)
Figure 56. Turkey Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 57. Saudi Arabia Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 58. UAE Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 59. Biogen Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
Figure 60. Pfizer Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
Figure 61. Roche Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
Figure 62. Novartis Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
Figure 63. Sanofi Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
Figure 64. Teva Pharmaceuticals Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
Figure 65. Orion Pharma Ltd Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
Figure 66. UCB S.A Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
Figure 67. ACADIA Pharmaceuticals Inc. Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
Figure 68. Lundbeck Pharmaceuticals Italy S.p.A. Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
Figure 69. Mitsubishi Tanabe Pharma America Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
